Scalable asymmetric synthesis of a key fragment of Bcl-2/Bcl-xL inhibitors

被引：5

作者：

Laclef, Sylvain ^{[1
,2
,3
,4
]}

Taillier, Catherine ^{[1
,2
,3
,4
]}

Penloup, Christine ^{[5
]}

Viger, Aurelie ^{[5
]}

Briere, Jean-Francois ^{[1
,2
,3
,4
]}

Hardouin, Christophe ^{[5
]}

Levacher, Vincent ^{[1
,2
,3
,4
]}

机构：

[1] Normandie Univ, COBRA, UMR 6014 & FR3038, F-76821 Mont St Aignan, France

[2] Univ Rouen, F-76821 Mont St Aignan, France

[3] INSA Rouen, F-76821 Mont St Aignan, France

[4] CNRS, IRCOF, F-76821 Mont St Aignan, France

[5] Oril Ind, F-76210 Bolbec, France

来源：

RSC ADVANCES | 2014年 / 4卷 / 75期

关键词：

BCL-2 FAMILY PROTEINS; REFORMATSKY REACTION; DUAL INHIBITORS; CELL-DEATH; POTENT; DISCOVERY; ANTAGONISTS; DERIVATIVES; REGULATORS; APOPTOSIS;

D O I：

10.1039/c4ra07821g

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The asymmetric synthesis of a 1,3-diamine building block for the elaboration of Bcl-2 and Bcl-(xL) protein inhibitors is described through two key steps: (1) a highly diastereoselective aza-Reformatsky reaction, and (2) a chemoselective amination under Mitsunobu conditions. This synthetic sequence was also demonstrated to be successfully amenable to a large-scale synthesis.

引用

页码：39817 / 39821

页数：5

共 50 条

[1] Towards the next generation of dual Bcl-2/Bcl-xL inhibitors
Varnes, Jeffrey G.
Gero, Thomas
Huang, Shan
Diebold, R. Bruce
Ogoe, Claude
Grover, Paul T.
Su, Mei
Mukherjee, Prasenjit
Saeh, Jamal Carlos
MacIntyre, Terry
Repik, Galina
Dillman, Keith
Byth, Kate
Russell, Daniel John
Ioannidis, Stephanos
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (14) : 3026 - 3033
[2] Studies leading to potent, dual inhibitors of bcl-2 and Bcl-xL
Bruncko, Milan
Oost, Thorsten K.
Belli, Barbara A.
Ding, Hong
Joseph, Mary K.
Kunzer, Aaron
Martineau, Darlene
McClellan, William J.
Mitten, Michael
ng, Shi-Chu Ng
Nimmer, Paul M.
Oltersdorf, Tilman
Park, Cheol-Min
Petros, Andrew M.
Shoemaker, Alexander R.
Song, Xiaohong
Wang, Xilu
Wendt, Michael D.
Zhang, Haichao
Fesik, Stephen W.
Rosenberg, Saul H.
Elmore, Steven W.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) : 641 - 662
[3] Fragment-Based Deconstruction of Bcl-xL Inhibitors
Barelier, Sarah
Pons, Julien
Marcillat, Olivier
Lancelin, Jean-Marc
Krimm, Isabelle
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) : 2577 - 2588
[4] RNA-DIRECTED SYNTHESIS OF BCL-2/BCL-XL PEPTIDE INHIBITOR
Di Pisa, M.
Seitz, O.
[J]. JOURNAL OF PEPTIDE SCIENCE, 2016, 22 : S162 - S162
[5] Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XL and BCL-2
Roy, Michael J.
Vom, Amelia
Okamoto, Toru
Smith, Brian J.
Birkinshaw, Richard W.
Yang, Hong
Abdo, Houda
White, Christine A.
Segal, David
Huang, David C. S.
Baell, Jonathan B.
Colman, Peter M.
Czabotar, Peter E.
Lessene, Guillaume
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (09) : 5447 - 5469
[6] Effects of Bcl-2/Bcl-xL Inhibitors on Pulmonary Artery Smooth Muscle Cells
Rybka, Vladyslava
Suzuki, Yuichiro J.
Shults, Nataliia, V
[J]. ANTIOXIDANTS, 2018, 7 (11):
[7] Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
Westhoff, Mike-Andrew
Schuler-Ortoli, Marie
Zerrinius, Daniela
Hadzalic, Amina
Schuster, Andrea
Strobel, Hannah
Scheuerle, Angelika
Wong, Tiana
Wirtz, Christian Rainer
Debatin, Klaus-Michael
Peraud, Aurelia
[J]. PHARMACEUTICALS, 2022, 15 (01)
[8] BCL-2 AND BCL-XL: POTENTIAL TARGETS FOR INHIBITION BY siRNA
Yakobson, E.
Vestin, A.
Weinstein, J.
Sergeyev, V.
Mandel, M.
Khazanov, E.
Barenholz, Y.
Agami, R.
Bank, I.
Sidi, Y.
[J]. ANTICANCER RESEARCH, 2004, 24 (5D) : 3634 - 3634
[9] Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL
Daver, Naval
Konopleva, Marina
[J]. BLOOD, 2016, 128 (10) : 1316 - 1317
[10] Unknotting the roles of Bcl-2 and Bcl-xL in cell death
Kim, R
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) : 336 - 343

← 1 2 3 4 5 →